The MelanoPredict project, led by OncoFactory and by Pr Stéphane Dalle, a dermatologist specialized in melanoma, won in 2018 the 2nd Lyonbiopôle / HCL Clinical Innovation Call.
The aim of this project is to model sensitivity/resistance to first-line drug treatment in our AVI-PDX technology.
The project will benefit from operational support from HCL, as well as financial support up to 100,000 euros. This support will help the development of melanoma biomarkers associated with clinical outcome for patients with first-line drug treatment.
Thanks to APICIL, OncoFactory is focusing its R&D effort on developing biomarkers and assessing drug candidates for Neuroblastoma and Malignant Germ Cell tumors.
Other R&D programs
Please contact us for partnership to work on breakthrough scientific projects.
Primary melanoma patient sample 48h post-graft